Literature DB >> 18312547

Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.

Ahmed Idbaih1, Mathilde Kouwenhoven, Judith Jeuken, Catherine Carpentier, Thierry Gorlia, Johan M Kros, Pim French, Johannes L Teepen, Olivier Delattre, Jean-Yves Delattre, Martin van den Bent, Khê Hoang-Xuan.   

Abstract

The chromosome (chr) 1p deletion is a favorable biomarker in oligodendroglial tumors and is even more powerful a marker when combined with chr 19q loss. As a result, the 1p deletion is taken into account more and more in clinical trials and the management of patients. However, the laboratory technique implemented for detection of this biomarker has been a topic of debate. To illustrate the usefulness of evaluating multiple loci, we here report two anaplastic oligodendrogliomas that were investigated using fluorescent in situ hybridization (FISH) and bacterial artificial chromosome (BAC)-array-based comparative genomic hybridization (aCGH). Indeed, segmental analysis using FISH, limited to chr 1p36 was unable to discriminate between complete and partial deletions of chrs 1p. However, complete and partial deletions of 1p are reported to have distinct clinical outcomes. Our results illustrate that aCGH (or other multiple loci technologies) provide complementary information to single locus technologies such as FISH because multiple loci technologies can evaluate the extent of the chr 1p deletion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312547     DOI: 10.1111/j.1440-1789.2008.00863.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  9 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

Review 2.  A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Authors:  Martin J van den Bent; Michael Weller; Patrick Y Wen; Johan M Kros; Ken Aldape; Susan Chang
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

Review 3.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

4.  Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

Authors:  Mathilde C M Kouwenhoven; Thierry Gorlia; Johan M Kros; Ahmed Ibdaih; Alba A Brandes; Jacolien E C Bromberg; Karima Mokhtari; Sjoerd G van Duinen; Johannes L Teepen; Pieter Wesseling; Fanny Vandenbos; Wolfgang Grisold; László Sipos; Rene Mirimanoff; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

5.  Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Authors:  Lale Erdem-Eraslan; Lonneke A Gravendeel; Johan de Rooi; Paul H C Eilers; Ahmed Idbaih; Wim G M Spliet; Wilfred F A den Dunnen; Johannes L Teepen; Pieter Wesseling; Peter A E Sillevis Smitt; Johan M Kros; Thierry Gorlia; Martin J van den Bent; Pim J French
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

6.  Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.

Authors:  Umma Habiba; Hirokazu Sugino; Roumyana Yordanova; Koki Ise; Zen-Ichi Tanei; Yusuke Ishida; Satoshi Tanikawa; Shunsuke Terasaka; Ken-Ichi Sato; Yuuta Kamoshima; Masahiko Katoh; Motoo Nagane; Junji Shibahara; Masumi Tsuda; Shinya Tanaka
Journal:  Acta Neuropathol Commun       Date:  2021-05-21       Impact factor: 7.578

7.  MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Authors:  Marta Mellai; Oriana Monzeglio; Angela Piazzi; Valentina Caldera; Laura Annovazzi; Paola Cassoni; Guido Valente; Susanna Cordera; Cristina Mocellini; Davide Schiffer
Journal:  J Neurooncol       Date:  2012-05       Impact factor: 4.506

8.  The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.

Authors:  Martinus P G Broen; Marion Smits; Maarten M J Wijnenga; Hendrikus J Dubbink; Monique H M E Anten; Olaf E M G Schijns; Jan Beckervordersandforth; Alida A Postma; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 13.029

9.  H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Authors:  Aldo Scarpa; Valeria Barresi; Serena Ammendola; Nicolò Caldonazzi; Michele Simbolo; Maria Liliana Piredda; Matteo Brunelli; Pietro Luigi Poliani; Giampietro Pinna; Francesco Sala; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2021-06-24       Impact factor: 4.535

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.